ArticleLa Radiologia medica2026
High-fidelity super-resolution CT radiomics for non-invasive EGFR mutation prediction in lung adenocarcinoma: a multi-center pooled analysis.
Article in La Radiologia medica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveTo develop and validate a high-fidelity super-resolution (SR)-enhanced radiomics framework using a Residual Channel Attention Network (RCAN) for non-invasive EGFR mutation prediction in lung adenocarcinoma (LUAD).
methodsThis retrospective multi-center study included 373 patients, partitioned into training (n = 298) and testing (n = 75) sets. CT images were reconstructed to a 1024 × 1024 matrix via RCAN to restore latent high-frequency textures. A standardized pipeline-including ComBat harmonization, ICC-based fidelity filtering, and LASSO regression-was employed to extract and select resolution-invariant features. Five machine learning classifiers were evaluated, and a combined nomogram integrated the SR-enhanced signature with clinical predictors. Model performance was assessed using AUC, DeLong tests, and decision curve analysis (DCA), with interpretability provided by SHAP analysis.
resultsThe SR-enhanced model significantly outperformed the original-resolution (OR) baseline, increasing the AUC from 0.60 (95% CI: 0.47-0.74) to 0.84 (95% CI: 0.75-0.93) in the testing set (P < 0.001). Consistent performance was maintained across imaging centers (P = 0.555) and histological subtypes. The combined nomogram achieved a robust AUC of 0.86 (95% CI: 0.78-0.94), demonstrating superior calibration and clinical net benefit. SHAP analysis revealed that glszm_ZoneVariance-a marker of intratumoral heterogeneity-was the predominant predictor revealed via SR reconstruction.
conclusionRCAN-driven SR reconstruction effectively addresses CT resolution limitations, capturing fine-grained radiogenomic signatures critical for molecular phenotyping. This high-fidelity framework offers a robust, non-invasive decision-support tool for personalized precision oncology in LUAD.
Indexed as
Identifiers
42340655What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.